Antithrombotic prophylaxis of no benefit in symptomatic outp

Delhi: Results from two randomized trials indicate that routine use of antithrombotic therapies to prevent thromboembolic complications is futile among symptomatic outpatients with COVID-19. The...

Related Keywords

Zurich , Züsz , Switzerland , Delhi , India , Belgium , Brasschaat , Region Flamande , Stefano Barco , Department Of Cardiology , University Hospital Zurich , Department Of Angiology , Frank Cools , General Hospital Klina , Monitoring Board , Data Safety , Between Aug , Lancet Haematology , Outpatients , Antithrombotic , Prophylaxis , Covid 19 , Low Molecular Weight Heparin , Enoxaparin , Thromboprophylaxis , Respiratory Infection , Critically Ill Patients , Thic Trial , Covid Trial , Coronavirus ,